|
| Press Releases |
|
 |
|
| Tuesday, September 6, 2022 |
|
|
Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022 |
| Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2022, which is taking place virtually and in-person in Paris, France from September 9 to 13. more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Eisai Inc. Collaborates with C2N to Build Awareness and Real-World Evidence for Blood-based Assays |
| Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has entered into a memorandum of understanding with C2N Diagnostics ("C2N") that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including Alzheimer's disease (AD), may help patients receive a timely diagnosis and appropriate treatment. more info >> |
|
| Tuesday, August 9, 2022 |
|
|
Eisai and Lifenet Enter Into Capital and Business Alliance Agreement Aimed at Building Ecosystem to Reduce Burden of Medical and Nursing Care |
| Eisai Co., Ltd. and LIFENET INSURANCE COMPANY announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in Japan's aging society. more info >> |
|
| Thursday, August 4, 2022 |
|
|
Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022 |
| Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new findings on a subcutaneous formulation of lecanemab (BAN2401) and the modeling simulation of the impact of ApoE4 genotype. more info >> |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) today announced that the Phase 3 LEAP-002 trial investigating LENVIMA. more info >> |
|
| Tuesday, July 26, 2022 |
|
|
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. more info >> |
|
|
Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022 |
| Eisai Co. Ltd announced today that the company will present research from its Alzheimer's disease (AD) pipeline, including new data for lecanemab (BAN2401). more info >> |
|
| Wednesday, July 6, 2022 |
|
|
U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application of Lecanemab |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) under the accelerated approval pathway for lecanemab. more info >> |
|
| Tuesday, June 28, 2022 |
|
|
E.Design Insurance and Eisai Enter Into Business Alliance |
| E.design Insurance Co., Ltd., a direct non- life insurance company of the Tokio Marine Group, and Eisai Co., Ltd. announced today that both companies have entered into a business alliance agreement aiming to realize a society where people can safely enjoy driving for a longer period of their lives in anticipation of the advent of super-aging society, under the theme of "Improving Brain Health (brain performance) for Safe Driving." more info >> |
|
| Friday, June 24, 2022 |
|
|
Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglected Tropical Diseases |
| Eisai Co., Ltd. announced today that Eisai has signed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda, and expressed Eisai's continued support for the elimination of NTDs towards the achievement of a road map for NTDs 2021-2030 launched by the World Health Organization (WHO). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TANAKA's New Head Office, TANAKA Building Received The GOOD DESIGN AWARD 2025 
Nov 7, 2025 4:00 JST
|
|
|
Honda Unveils Next-generation Technologies at "Honda Automotive Technology Workshop" for Electrified Models to be Launched in Second Half of 2020s
Nov 6, 2025 22:44 JST
|
|
|
Market Value Lower Than Cash Assets? It's Time to Reevaluate NIVF
Nov 6, 2025 21:36 HKT/SGT
|
|
|
Winvest Group Announces Strategic Partnership with Greater Bay Area RWA Incubator; Southeast Asia Headquarters to Be Established in Malaysia
Nov 6, 2025 21:30 HKT/SGT
|
|
|
K.Wah Group Supports 2025 Legislative Council Election
Nov 6, 2025 21:09 HKT/SGT
|
|
|
Ten organizations have jointly launched a project titled "Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry"
Nov 6, 2025 22:00 JST
|
|
|
Fujitsu to develop new chatbot for Japan Pension Service
Nov 6, 2025 21:24 JST
|
|
|
The 17th Hong Kong International Wine & Spirits Fair Opens Today
Nov 6, 2025 19:16 HKT/SGT
|
|
|
Stripe and NEC to Provide Face Recognition Payment Service via Stripe Terminal
Nov 6, 2025 17:30 JST
|
|
|
Excent Capital Announces Swap-Free Trading on All U.S. Stocks and Indices
Nov 6, 2025 16:00 HKT/SGT
|
|
|
ESA, MediaTek, Eutelsat, Airbus, Sharp, ITRI, and R&S Announce World's First Rel-19 5G-Advanced NR-NTN Connection over OneWeb LEO Satellites
Nov 6, 2025 17:00 JST
|
|
|
Hybrid Dump Truck Demonstration Test at South African Mining Site Selected by UNIDO's Industrial Cooperation Programme
Nov 6, 2025 16:16 JST
|
|
|
Mitsubishi Power Receives Contract to Upgrade Existing Boiler Equipment at the O Mon 1 Thermal Power Plant in Vietnam
Nov 6, 2025 16:01 JST
|
|
|
Tune Talk partners with Truecaller to Enhance Customer Experience and Trust Across Malaysia's Telecom Sector
Nov 6, 2025 15:00 HKT/SGT
|
|
|
MHI and ICM Form Strategic Alliance to Advance Ethanol Dehydration Efficiency
Nov 6, 2025 15:38 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
